Dermata Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Dermata Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • Dermata Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.23M, a 78% decline year-over-year.
  • Dermata Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$11.5M, a 53.1% decline year-over-year.
  • Dermata Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$8.04M, a 16.9% increase from 2022.
  • Dermata Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$9.67M, a 23.1% decline from 2021.
  • Dermata Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$7.86M, a 148% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$8.04M +$1.63M +16.9% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-21
2022 -$9.67M -$1.82M -23.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 -$7.86M -$4.68M -148% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-21
2020 -$3.17M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.